Company Overview of Arecor Limited
Arecor Limited provides stabilization technology solutions to pharmaceutical and biotech companies. It partners with pharmaceutical and biotech companies to enhance the commercial value and practical utility of various types of proteins, as well as in various applications, such as vaccines, therapeutic proteins, and proteins used in medical devices. The company engages in developing products in the areas of infectious diseases/vaccines, diabetes, haematology, hormone and enzyme replacement therapies, immunology and rheumatology, and oncology; and high dosage medication that can be self-administered by patients by using a pre-filled syringe. It also enables high concentration of the antibody ...
2 Cambridge Science Park
Cambridge, CB4 0FE
Founded in 2006
Key Executives for Arecor Limited
Chief Executive Officer and Director
Compensation as of Fiscal Year 2015.
Arecor Limited Key Developments
Arecor Announces Executive Changes
Jun 11 15
Tom Saylor is retiring as CEO of Arecor, the position in which he has effectively served for the past 8 years. Although Tom has decided to retire from full time responsibility as CEO he has been asked by the Board to remain as a non-Executive Director of Arecor where he can continue to contribute his network, skills and experience to the ongoing success of the business. Tom will be succeeded by Dr. Sarah Howell who has served as Chief Operating Officer and Vice President for Corporate Development. Sarah brings very considerable experience from executive roles in the pharmaceutical industry including, most recently, as Vice President for CMC and Technical Development of BTG plc.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries